Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer-Reference-Cited by-同舟云学术

Real-world Outcomes of Cyclin-dependent Kinase Inhibitors Continued Beyond First Disease Progression in Hormone Receptor-positive Metastatic Breast Cancer

Published:2021-06 Issue:3 Volume:21 Page:205-209
ISSN:1526-8209
Container-title:Clinical Breast Cancer
language:en
Short-container-title:Clinical Breast Cancer

Author:

Samuel Eziokwu Akaolisa,Varella Leticia,Lynn Kruse Megan,Jia Xuefei,Moore Halle C.F.,Thomas Budd George,Abraham Jame,Montero Alberto J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference16 articles.

1. Global cancer in women: burden and trends;Torre;Cancer Epidemiol Biomarkers Prev,2017

2. US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status;Howlader;J Natl Cancer Inst,2014

3. Endocrine therapy for hormone receptor-positive metastatic breast cancer: American society of clinical oncology guideline;Rugo;J Clin Oncol,2016

4. Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies;Murphy;Endocr Relat Cancer,2016

5. Updates on the CDK4/6 inhibitory strategy and combinations in breast cancer;Sobhani;Cells,2019

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Comparative analysis of adverse events associated with CDK4/6 inhibitors based on FDA’s adverse event reporting system: a case control pharmacovigilance study;BMC Pharmacology and Toxicology;2024-08-09

2. Therapy for Hormone Receptor-Positive, Human Epidermal Growth Receptor 2-Negative Metastatic Breast Cancer Following Treatment Progression via CDK4/6 Inhibitors: A Literature Review;Breast Cancer: Targets and Therapy;2024-04

3. Estrogen receptor positive breast cancer: contemporary nuances to sequencing therapy;Medical Oncology;2023-12-16

4. Treatment options for patients with hormone receptor-positive, HER2-negative advanced-stage breast cancer: maintaining cyclin-dependent kinase 4/6 inhibitors beyond progression;Frontiers in Oncology;2023-10-04

5. MicroRNA regulation of the serine synthesis pathway in endocrine-resistant breast cancer cells;Endocrine-Related Cancer;2023-08-31